Zumsemetinib

Phase 2Small molecule

WWashington University School of Medicine

Zumsemetinib is one of 6 small molecule programs targeting Bone Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisRecruiting

Bone MetastasisPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Bone Metastasis

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

12 2

Duragesic

CCephalon

Approved

—3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 4

Iressa

AstraZeneca

Preclinical

1 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Zumsemetinib

WWashington University School of Medicine

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 1/2Recruiting

Bone Metastasis

NCT06374459

Clinical

Trials by Indication[1]

Bone Metastasis1 trial

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06374459·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zumsemetinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zumsemetinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zumsemetinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Zumsemetinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Bone Metastasis1 trial

References

Drug Info

Quick Facts

Related News